March 9, 2018
Authored and Edited by Bonnie Fletcher Price, Ph.D.; Thomas L. Irving
On February 16, 2018, FDA issued draft guidance describing the standardized format for electronic submission of data and information for all major (i.e., pivotal) studies used to support safety and efficacy claims in NDAs, BLAs regulated by CDER, and INDs in advance of a planned NDA, BLA, or supplemental submission. The guidance is part of FDA’s ongoing effort to standardize formatting for Bioresearch Monitoring (BIMO) inspection submissions to CDER.
To facilitate BIMO inspection planning, site selection and the conduct of inspections, FDA requests that applicants provide: (1) a comprehensive and readily located table listing all clinical sites that participated in clinical studies; (2) a table listing all entities whom the sponsor has contracted clinical study-related activities; and (3) protocols, protocol amendments, and annotated case report forms.
To allow verification of key study data during inspections, FDA requests that applicants provide subject-level data line listings by clinical site, including studies with different treatment indications. In addition, applicants should submit summary-level clinical site datasets containing data from pivotal studies to support safety and efficacy claims, including independent data for each study in cases where clinical investigator sites are involved in multiple studies.
Specifications for the electronic format and additional information on submitting the clinical study-level information, the subject-level data line listings by clinical site, and the summary-level clinical dataset is provided in the Bioresearch Monitoring Technical Conformance Guide.
Readers are encouraged to read the draft guidance, also available on FDA’s website. Comments and suggestions regarding the draft guidance should be submitted to FDA by April 17, 2018.
drugs, Food and Drug Administration (FDA), FDA Guidance, new drug application (NDA), Biologic License Application (BLA), Investigational New Drug Application (INDA)
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Conference
Best Practices in Intellectual Property– A Decade of Dedication to IP Excellence
April 8-9, 2024
Tel Aviv
INCONTESTABLE® Blog
Winning the Battle but Not the War: Disclaimer Requirement Overturned, Section 2(d) Objection Upheld
March 28, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.